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Background Diabetes mellitus (DM) is a consistent, independent predictor of adverse prognosis in stent trials. Drug-eluting stents (DES) reduced 
restenosis compared with bare-metal stents (BMS) in DM pts. Although sirolimus-eluting stent (SES) compared with paclitaxel-eluting stent (PES) 
is typically associated with lower in-stent late loss in DM pts, the clinical outcomes data have been conflicting. We compared outcomes of DM pts 
treated with PCI using SES vs PES vs BMS in the setting of acute coronary syndromes (ACS) in the randomized ACUITY trial.
Methods and Results In the ACUITY trial, 1654 pts with DM had stent-assisted PCI with SES (n=513), PES (n=609), or BMS (n=532). Clinical 
outcomes at 30 days did not differ significantly in pts with different stents. At 1 year, pts treated with BMS had significantly higher mortality than 
patients treated with PES. By multivariable analysis, 1-year composite ischemia was predicted by DM (p=0.019), previous PCI (p<0.001), chronic 
renal insufficiency (p<0.001), and total stent length (p<0.001); the use of DES predicted freedom from composite ischemia at 1 year (p=0.003).
Conclusion BMS were used in approximately 1/3 of moderate to high risk ACS diabetic pts treated with PCI in the ACUITY trial. After adjustment 
for multiple covariates, the use of BMS in pts was associated with increased 1-year composite ischemia. Diabetic pts treated with PES vs. SES had 
comparable 30-day and 1-year outcomes. 
Events, %
Diabetic pts treated with stent 
n=1654
P
SES
n=513 pts
PES
n=609 pts
BMS
n=532 pts
30-day
Death 1.2% 1.0% 2.1% 0.27
MI 5.9% 6.4% 5.5% 0.79
Death/MI 6.6% 7.2% 7.2% 0.92
Unplanned revasc. 2.6% 2.8% 3.4% 0.69
Composite ischemia* 8.2% 8.4% 8.8% 0.93
Major bleeding 7.6% 7.4% 7.4% 0.98
Net clinical outcome† 14.3% 14.0% 13.7% 0.97
Definite/probable stent thrombosis (ARC) 1.6% 1.0% 2.6% 0.09
1-year
Death 5.0% 4.2% 8.8% 0.048
MI 10.6% 8.7% 8.6% 0.59
Death/MI 14.1% 11.5% 15.1% 0.46
Unplanned revasc. 13.7% 12.5% 11.3% 0.54
Composite ischemia* 21.7% 19.6% 21.5% 0.79
Definite/probable stent thrombosis (ARC) 2.9% 1.3% 2.8% 0.18
* Death, MI or unplanned revascularization; † Composite ischemia or major bleeding
